Y-Trap, Inc. Has Signed A Collaboration And License Agreement With Merck Kgaa, Darmstadt, Germany, A Leading Science And Technology Company, For The Exclusive Development Of Multiple Specific Antibody-Ligand Traps For Cancer Immunotherapy.The Collaboration Leverages Y-Trap'S Proprietary Platform Of Multifunctional Antibody-Ligand Traps For Immuno-Oncology. The Y-Trap Platform Exploits Combinatorial Protein Engineering To Counteract Key Determinants Of Immune Dysfunction In The Tumor Microenvironment. Y-Trap And Merck Kgaa, Darmstadt, Germany, Will Collaborate To Explore The Pharmacology Of Y-Trap Multifunctional Proteins And Merck Kgaa, Darmstadt, Germany, Will Be Responsible For All Development, Manufacturing And Commercialization Activities.Under The Agreement, Merck Kgaa, Darmstadt, Germany, Will Provide Y-Trap With An Upfront Payment In Addition To Milestone Payments And Royalties Based On The Achievement Of Specific Pre-Clinical, Clinical Development, Regulatory, And Commercial Milestones."Cancers Evolve To Counteract And Defeat Immune Surveillance By Co-Opting And Amplifying Natural Mechanisms Of Immune Suppression," Said Atul Bedi, Md, Mba, Co-Founder And Chief Scientist Of Y-Trap, Inc. "Y-Trap'S Multifunctional Antibody-Ligand Traps Are Designed To Counteract Key Determinants Of Immune Tolerance To Entrain More Effective Antitumor Immunity. We Look Forward To Dovetailing The Respective Strengths Of Y-Trap And Merck Kgaa, Darmstadt, Germany, To Advance The Development Of Multiple Molecules From This Platform For Cancer Immunotherapy."
